Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from Argent Biopharma ( (AU:RGT) ).
Argent Biopharma has announced its delisting from the London Stock Exchange, effective from December 31, 2024. Following this, shareholders will need to transfer their Depositary Interests from the CREST system to the CHESS system to facilitate trading on the Australian Stock Exchange, indicating a strategic shift in the company’s market operations.
More about Argent Biopharma
Argent Biopharma Limited is an innovative company in the biopharmaceutical sector focusing on drug discovery and development using multidisciplinary methods like nanotechnology. It specializes in creating multi-target therapies for comprehensive disease management, particularly relating to the central nervous system and immunology treatments.
YTD Price Performance: -61.21%
Average Trading Volume: 76,143
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $6.05M
See more insights into RGT stock on TipRanks’ Stock Analysis page.
